Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Group: GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk

Page standards status: Informative

version: 76; Last updated: 2025-10-09 20:58:38+0000

Profile: ExposureGroup

Artifact Author: Computable Publishing®: MAGIC-to-FEvIR Converter:

RelatesTo

  • type: part-of
  • targetReference: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)

CiteAs:

GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236535. Revised 2025-10-09. Available at: https://fevir.net/resources/Group/236535. Computable resource at: https://fevir.net/resources/Group/236535#json.

url: https://fevir.net/resources/Group/236535

identifier: FEvIR Object Identifier/236535, FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-intervention-group-MAGIC-5288-j1Wqrn-intervention-85390-I-85789

title: GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk

status: Active

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

description:

Glucagon-Like Peptide-1 (GLP-1) receptor agonists

UseContexts

-CodeValue[x]
*Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication: Evidence CommunicationExposureGroup

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

type: Person

membership: Enumerated

combinationMethod: All of

characteristic

code: Member of

value: Adults with type 2 diabetes and established CVD (but no CKD)

exclude: false

description:

inclusion in Adults with type 2 diabetes with moderate CV risk

characteristic

code: Exposed to

value: Glucagon-Like Peptide-1 (GLP-1) receptor agonists

exclude: false

description:

received GLP-1 RA